argenex SE $ARGX Shares Acquired by Quantinno Capital Management LP

Quantinno Capital Management LP increased its position in shares of argenex SE (NASDAQ:ARGX) by 11.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,148 shares of the company’s stock after buying an additional 1,111 shares during the quarter. Quantinno Capital Management LP’s holdings in argenex were worth $8,141,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. grew its position in argenex by 2.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock worth $372,000 after acquiring an additional 12 shares during the period. Valeo Financial Advisors LLC raised its position in argenex by 0.9% in the fourth quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock valued at $1,153,000 after purchasing an additional 12 shares during the period. CI Investments Inc. raised its position in argenex by 2.6% in the fourth quarter. CI Investments Inc. now owns 469 shares of the company’s stock valued at $394,000 after purchasing an additional 12 shares during the period. Allworth Financial LP lifted its stake in shares of argenex by 12.7% in the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock valued at $97,000 after purchasing an additional 13 shares during the last quarter. Finally, WPG Advisers LLC lifted its stake in shares of argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock valued at $63,000 after purchasing an additional 13 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Price Performance

Shares of argenex stock opened at $844.50 on Wednesday. The business has a 50-day moving average of $876.87 and a 200 day moving average of $818.24. argenex SE has a 12 month low of $631.47 and a 12 month high of $953.58. The stock has a market capitalization of $52.83 billion, a price-to-earnings ratio of 32.43, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.86 by $1.46. The company had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. Equities research analysts anticipate that argenex SE will post 28.05 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on ARGX shares. Wells Fargo & Company raised their price objective on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Citizens Jmp decreased their target price on shares of argenex from $944.00 to $932.00 and set a “market outperform” rating on the stock in a research report on Friday, July 24th. Oppenheimer increased their target price on shares of argenex from $1,014.00 to $1,037.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. HC Wainwright reiterated a “buy” rating and set a $940.00 price target on shares of argenex in a research report on Thursday, June 25th. Finally, Morgan Stanley boosted their price target on shares of argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,056.89.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.